EP3846810
Langvarandi kvöldskömmtun á lasmidítan til fyrirbyggingar á mígreni
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
3.9.2019EP published:
18.10.2023EP application number:
19773583.0
EP translation filed:
27.11.2023Grant published:
15.12.2023EPO information:
European Patent Register
Max expiry date:
2.9.2039Expiry date:
2.9.2026Next due date:
30.9.2026
Title in English:
CHRONIC NIGHTLY DOSING OF LASMIDITAN FOR MIGRAINE PREVENTIONLanguage of the patent:
English
Timeline
Today
3.9.2019EP application
18.10.2023EP Publication
27.11.2023Translation submitted
15.12.2023Registration published
2.9.2026Expires
Owner
Name:
Eli Lilly and CompanyAddress:
Lilly Corporate Center, Indianapolis, IN 46285, US
Inventor
Name:
CONLEY, Robert RussellAddress:
Indianapolis, Indiana 46206-6288, US
Name:
DAVAR, GudarzAddress:
Indianapolis, Indiana 46206-6288, US
Name:
JOHNSON, Kirk WillisAddress:
Indianapolis, Indiana 46206-6288, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201862726585 PDate:
4.9.2018Country:
US
Classification
Categories:
A61K 31/444, A61P 25/06
Annual fees
Number
Paid
Expires
Payer
Number: 6
Paid: 22.8.2024
Expires: 2.9.2025
Payer: Árnason Faktor ehf.
Number: 7
Paid: 21.8.2025
Expires: 2.9.2026
Payer: Árnason Faktor ehf.